Clinical Trial: Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498634) titled 'Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS' on March 18.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study.

Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance treatment and 8 weeks for safety follow-up.

Study Start Date: Sept. 21, 2023

Study Type: INTERVENTIONAL

Condition: Phase III

Intervention: DRUG: XKH004

Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection

DRUG: Placebo

Placebo

Rec...